Twist Bioscience Corporation (NASDAQ:TWST) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $98.30.

TWST has been the topic of a number of research reports. Evercore lowered shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price on the stock. in a research note on Monday, July 6th. Canaccord Genuity Group increased their price target on shares of Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday. UBS Group set a $89.00 price objective on Twist Bioscience in a research report on Monday, June 15th. Finally, Leerink Partners set a $110.00 target price on Twist Bioscience in a report on Thursday, July 16th.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $115.01 on Thursday. The stock has a fifty day moving average of $87.51 and a 200 day moving average of $63.50. Twist Bioscience has a 52 week low of $23.30 and a 52 week high of $115.56. The firm has a market capitalization of $7.16 billion, a price-to-earnings ratio of -51.81 and a beta of 2.14. The company has a quick ratio of 2.42, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. During the same period in the previous year, the firm posted $0.33 earnings per share. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, research analysts expect that Twist Bioscience will post -2.02 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Dennis Cho sold 14,205 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the sale, the insider directly owned 105,141 shares in the company, valued at $9,436,404.75. The trade was a 11.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 291 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $87.32, for a total value of $25,410.12. Following the completion of the transaction, the senior vice president owned 120,414 shares of the company’s stock, valued at approximately $10,514,550.48. This trade represents a 0.24% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 50,211 shares of company stock worth $4,199,331 over the last quarter. Company insiders own 3.08% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Trifecta Capital Advisors LLC bought a new stake in Twist Bioscience during the second quarter worth about $63,000. Western Wealth Management LLC bought a new position in shares of Twist Bioscience during the first quarter valued at approximately $31,000. Strs Ohio purchased a new position in shares of Twist Bioscience during the first quarter valued at approximately $33,000. GAMMA Investing LLC boosted its position in shares of Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after purchasing an additional 185 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in shares of Twist Bioscience by 89.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after purchasing an additional 453 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.